Hu Jianpei, Wu Chunyu, Zhao Xueying, Liu Chaodong
Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Onco Targets Ther. 2017 Jul 24;10:3709-3718. doi: 10.2147/OTT.S141652. eCollection 2017.
A consensus regarding the prognostic value of decreased miR-101 in human cancers has not been reached. This study aimed to comprehensively investigate the internal associations between loss of miR-101 expression and prognostic implications in patients with cancer.
All relevant literature in electronic databases, including PubMed, ISI Web of Science, and Embase, up to March 1, 2017 were searched. Correlations between decreased miR-101 and clinicopathological parameters were defined by odds ratios (ORs). The degree of association between reduced miR-101 and survival outcome was evaluated by pooled hazard ratios (HRs) and relevant 95% CIs.
Twelve eligible studies with 2,088 patients were included in this meta-analysis. Decreased miR-101 expression was closely connected with poor overall survival, with a pooled HR of 2.15 (95% CI 1.71-2.7, <0.001). This correlation was also revealed when stratified analysis was conducted with respect to ethnicity, cancer type, sample size, specimen source, and analysis model. However, decreased miR-101 was not associated with disease-free survival, recurrence-free survival, or progression-free survival, with a pooled HR of 1.59 (95% CI 0.83-3.03, =0.128), despite a positive trend. In addition, reduced miR-101 was intimately related to poorer tumor differentiation (OR 2.17, 95% CI 1.14-4.13; =0.019), advanced tumor classification (OR 5.25, 95% CI 3.39-8.12; <0.001), and higher TNM stage (OR 6.18, 95% CI 3.79-10.09; <0.001).
Our findings suggest that loss of miR-101 expression is correlated with worse overall survival in a variety of cancers, and could serve as a predictive indicator for clinicopathological features. Furthermore, miR-101 may become a feasible therapeutic target in most human cancers.
关于miR - 101表达降低在人类癌症中的预后价值尚未达成共识。本研究旨在全面探究miR - 101表达缺失与癌症患者预后影响之间的内在关联。
检索了截至2017年3月1日电子数据库（包括PubMed、ISI Web of Science和Embase）中的所有相关文献。通过比值比（OR）确定miR - 101降低与临床病理参数之间的相关性。通过合并风险比（HR）及相关的95%置信区间评估miR - 101降低与生存结局之间的关联程度。
本荟萃分析纳入了12项符合条件的研究，共2088例患者。miR - 101表达降低与总体生存率差密切相关，合并HR为2.15（95% CI 1.71 - 2.7，<0.001）。在按种族、癌症类型、样本量、标本来源和分析模型进行分层分析时，也显示出这种相关性。然而，miR - 101降低与无病生存率、无复发生存率或无进展生存率无关，合并HR为1.59（95% CI 0.83 - 3.03，P = 0.128），尽管有阳性趋势。此外，miR - 101降低与较差的肿瘤分化（OR 2.17，95% CI 1.14 - 4.13；P = 0.019）、晚期肿瘤分级（OR 5.25，95% CI 3.39 - 8.12；<0.001）和更高的TNM分期（OR 6.18，95% CI 3.79 - 10.09；<0.001）密切相关。
我们的研究结果表明，miR - 101表达缺失与多种癌症的总体生存率较差相关，并且可作为临床病理特征的预测指标。此外，miR - 101可能成为大多数人类癌症中一个可行的治疗靶点。
